Welcome to our dedicated page for Cardiff Oncology SEC filings (Ticker: CRDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardiff Oncology, Inc. filings document regulatory disclosures for a clinical-stage oncology company developing onvansertib and PLK1-inhibition programs. Recent Form 8-K reports cover financial results, business updates, Regulation FD presentation materials, CRDF-004 clinical disclosures in first-line RAS-mutated metastatic colorectal cancer and other material events tied to the company's development strategy.
The company's proxy and current reports also address board and executive governance, officer appointments and departures, separation agreements, compensation arrangements, equity awards and Nasdaq inducement grants. These filings include formal disclosure of risk themes common to clinical-stage biotechnology issuers, including clinical-trial uncertainty, financing needs, dependence on key personnel and operating disruptions.
Cardiff Oncology, Inc. (CRDF) – Form 4 Overview
On 06/26/2025, Director Gary W. Pace received a grant of 40,565 stock options with an exercise price of $3.16 per share under the company’s equity compensation plan. The options expire on 06/26/2035. After the grant, Mr. Pace beneficially owns 187,539 derivative securities (options) in total. The Form 4, filed on 06/27/2025, reports no open-market purchases or sales of common stock, and the holdings are reported as Direct (D) ownership. This filing reflects routine director compensation rather than an investment decision.
Cardiff Oncology (Nasdaq:CRDF) filed a Form 8-K detailing the 26 June 2025 Annual Meeting vote results.
- All seven director nominees were elected with roughly 20.5-21.2 M votes in favor and no votes against.
- Shareholders ratified BDO USA, P.C. as the independent auditor for FY 2025 (36.3 M for, 1.2 M against, 1.1 M abstain).
- An amendment raising the 2021 Equity Incentive Plan’s share reserve to 12.15 M shares passed (16.9 M for, 5.0 M against).
- The advisory say-on-pay resolution was approved (18.9 M for, 2.6 M against).
No other material business or operational updates were disclosed.